No 03 2017

Alvotech has announced the expansion of its capacity for assembly and packaging with the acquisition of Ivers-Lee Group, a family owned business with headquarters in Burgdorf, Switzerland specializing in providing assembly and packaging services for the pharmaceutical sector.

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy (surgery to remove the bladder).

We would like to thank our readers, subscribers and collaboration partners for a fruitful and eventful Q1 + Q2 2025, and we wish you all a most wonderful summer!

BioArctic’s founder, Professor Lars Lannfelt, will receive the prize for his pioneering contributions to the understanding of Alzheimer’s disease and to the development of the drug lecanemab.

The companies have entered into a supply and commercialization agreement for AVT10, Alvotech’s biosimilar candidate to Cimzia (certolizumab pegol).

Camurus has announced that the European Commission (EC) has granted Oczyesa, octreotide subcutaneous depot, marketing authorization for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs.

The company has been awarded grant and equity financing from the European Innovation Council (EIC) Accelerator, a funding initiative under the European Union's Horizon Europe program designed to support highly innovative start-ups with disruptive technologies.